Tafamidis Meglumine
Brand name: Vyndaqel
Rank #337 of 500 drugs by total cost
$31.0M
Total Cost
1,387
Total Claims
$31.0M
Total Cost
80
Prescribers
$22K
Cost per Claim
11
Beneficiaries
1,444
30-Day Fills
$387K
Avg Cost/Provider
17
Avg Claims/Provider
About Tafamidis Meglumine
Tafamidis Meglumine (sold as Vyndaqel) was prescribed 1,387 times by 80 Medicare Part D providers in 2023, costing the program $31.0M. At $22K per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 334 | Zolpidem Tartrate (Zolpidem Tartrate) | $31.3M | 3,144,599 |
| 335 | Lorazepam (Lorazepam) | $31.3M | 3,237,827 |
| 336 | Diphth,pertuss(Acell),tet Vac (Boostrix Tdap) | $31.2M | 466,555 |
| 337 | Tafamidis Meglumine (Vyndaqel) | $31.0M | 1,387 |
| 338 | Midodrine Hcl (Midodrine Hcl) | $30.9M | 383,390 |
| 339 | Sarilumab (Kevzara) | $30.5M | 6,822 |
| 340 | Dabrafenib Mesylate (Tafinlar) | $30.4M | 2,377 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology